Research programme: chondroitinases - Acorda Therapeutics

Drug Profile

Research programme: chondroitinases - Acorda Therapeutics

Alternative Names: Chondroitin sulfate proteoglycan lyases; Chondroitinase ABC−I; Recombinant chondroitinase AC; Recombinant chondroitinase B

Latest Information Update: 11 Apr 2012

Price : $50

At a glance

  • Originator Cambridge University Technical Services; Kings College London
  • Developer Acorda Therapeutics
  • Class Chondroitinases and chondroitin lyases; Recombinant proteins
  • Mechanism of Action Chondroitin lyase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Spinal cord injuries

Highest Development Phases

  • Preclinical Spinal cord injuries

Most Recent Events

  • 10 Apr 2012 Preclinical development is ongoing in US
  • 12 Feb 2008 Acorda Therapeutics is seeking partnership opportunities for this research programme
  • 09 Dec 2005 Data presented at the 35th Annual Meeting of the Society for Neuroscience (SfN-2005) have been added to the Neurological disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top